Original Research J Clin Psychiatry September 2023

Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study

JCP 2023;84(5):10.4088/JCP.23m14873

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Clinical Summary For adults with schizophrenia who struggle with long-term adherence, a 2-month long-acting injectable can reduce dosing frequency only if it maintains stability without adding tolerability problems. This analysis focuses on clinically stable patients with schizophrenia and addresses whether aripiprazole 2-month ready-to-use 960 mg performs comparably to aripiprazole once-monthly 400 mg over maintenance treatment. FAQ What did this study find about aripiprazole 2-month ready-to-use 960 mg in adults with schizophrenia?

Key Takeaways For stable outpatients with schizophrenia, the less frequent schedule did not lead to more dropouts in this 32-week trial; study completion was 79.3% (73/92 patients) with Ari 2MRTU 960 versus 67.7% (63/93 patients) with AOM 400 (P = .0954). Clinical Guide How do clinicians identify which adults with schizophrenia are appropriate candidates for aripiprazole 2-month ready-to-use 960 mg maintenance treatment? Clinical Guide How should clinicians start and monitor aripiprazole 2-month ready-to-use 960 mg in clinically stable adults with schizophrenia?